{"id":47637,"date":"2022-08-24T22:01:43","date_gmt":"2022-08-24T20:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/"},"modified":"2022-08-24T22:01:43","modified_gmt":"2022-08-24T20:01:43","slug":"alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/","title":{"rendered":"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors"},"content":{"rendered":"
\n

\n\u2013 Dr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies \u2013<\/i>\n<\/p>\n

\n\u2013 Served as Chief Scientific Officer and a Director of Bristol-Myers Squibb \u2013<\/i>\n<\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc.<\/a> (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades of senior leadership and board experience at biopharmaceutical companies. He served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb (BMS) and as a director on the company\u2019s board. During his tenure at BMS, he was instrumental in building the company\u2019s leading research position in immuno-oncology. Under his leadership, 14 new medicines came to market in multiple therapeutic areas including cardiometabolic disease, infectious disease, inflammatory disease, neuroscience and oncology.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are thrilled to welcome Elliott to our Board at an especially important and exciting time in our Company\u2019s history. As a deeply accomplished leader, Elliott will bring valuable experience to Alnylam and our Board as we continue to advance our RNAi therapeutics to transform the lives of patients afflicted with rare and prevalent diseases with unmet need,\u201d said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. \u201cWe look forward to his contributions in the years ahead.\u201d\n<\/p>\n

\n\u201cAlnylam has revolutionized RNAi as a new class of medicines that improve patients\u2019 lives,\u201d said Dr. Sigal. \u201cI am excited to join the Company at this critical inflection point and to work with the Board and management as we continue to grow the company\u2019s commercial portfolio and advance its RNAi therapeutic pipeline.\u201d\n<\/p>\n

\nDr. Sigal currently serves as co-chair of the Scientific Advisory Board for Amgen, Inc. and as a senior advisor to the healthcare team of New Enterprise Associates. He is a member of the Board of Directors for the public biotechnology companies Adaptimmune Therapeutics plc, Vir Biotechnology, Inc. and Surface Oncology, Inc., as well as the private companies Tessera Therapeutics and Affinia Therapeutics Inc. Prior Board positions include Spark Therapeutics, Inc. from 2014 to 2019, Mead Johnson Nutrition from 2009 to 2017 and BMS from 2011 to 2013.\n<\/p>\n

\nAbout Alnylam Pharmaceuticals<\/b>\n<\/p>\n

\nAlnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam\u2019s commercial RNAi therapeutic products are ONPATTRO\u00ae (patisiran), GIVLAARI\u00ae (givosiran), OXLUMO\u00ae (lumasiran), AMVUTTRA\u2122 (vutrisiran), and Leqvio\u00ae (inclisiran) being developed and commercialized by Alnylam\u2019s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its \u201cAlnylam P5x25\u201d strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com<\/a> and engage with us on Twitter at @Alnylam<\/a>, on LinkedIn<\/a>, or on Instagram<\/a>.\n<\/p>\n

\nAlnylam Forward Looking Statements<\/b>\n<\/p>\n

\nVarious statements in this release concerning Alnylam’s future expectations, plans and prospects, including, without limitation, Alnylam\u2019s views with respect to its aspiration to become a leading biotech company and the planned achievement of its \u201cAlnylam P5x25\u201d strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam\u2019s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam\u2019s efforts to mitigate the impact of the pandemic; the potential impact of the recent leadership transition on Alnylam\u2019s ability to attract and retain talent and to successfully execute on its \u201cAlnylam P5x25\u201d strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, including patisiran and vutrisiran; actions or advice of regulatory agencies and Alnylam\u2019s ability to obtain and maintain regulatory approval for its product candidates, including patisiran and vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam\u2019s ability to successfully expand the indication for ONPATTRO, AMVUTTRA or OXLUMO in the future; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam\u2019s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of current and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the \u201cRisk Factors\u201d filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAlnylam Pharmaceuticals, Inc.<\/b>\n<\/p>\n

\nChristine Regan Lindenboom
\n
(Investors and Media)
\n
+1-617-682-4340\n<\/p>\n

\nJosh Brodsky
\n
(Investors)
\n
+1-617-551-8276\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Dr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies \u2013 \u2013 Served as Chief Scientific Officer and a Director of Bristol-Myers Squibb \u2013 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47637","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Dr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies \u2013 \u2013 Served as Chief Scientific Officer and a Director of Bristol-Myers Squibb \u2013 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-24T20:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220824005664\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors\",\"datePublished\":\"2022-08-24T20:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/\"},\"wordCount\":1008,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005664\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/\",\"name\":\"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005664\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"datePublished\":\"2022-08-24T20:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005664\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005664\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors - Pharma Trend","og_description":"\u2013 Dr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies \u2013 \u2013 Served as Chief Scientific Officer and a Director of Bristol-Myers Squibb \u2013 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-24T20:01:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220824005664\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors","datePublished":"2022-08-24T20:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/"},"wordCount":1008,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220824005664\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/","name":"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220824005664\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","datePublished":"2022-08-24T20:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220824005664\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220824005664\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alnylam-announces-appointment-of-elliott-sigal-m-d-ph-d-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47637"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47637\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}